4-Chloro-3-(Trifluoromethyl) phenyl Isocyanate CAS 327-78-6 Puritas ≥99.0% Sorafenib Tosylate Factory intermedium
Commercial Supple Sorafenib Tosylate et intermedia:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolamide CAS:
4-Chloro-3-(Trifluoromethyl) phenyl Isocyanate CAS: 327-78-6
Nomen | 4-Chloro-3-(Trifluoromethyl) phenyl Isocyanate |
Synonyma | Isocyanicum Acidum 4-Chloro-3-(Trifluoromethyl) phenyl Ester |
CAS Number | 327-78-6 |
CATTUS Number | RF-PI167 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C8H3ClF3NO |
M. Pondus | 221.56 |
Liquescens punctum | 37.0~42.0℃ (lit.) |
Ferveret | 86.0~90.0 14 mmHg (lit.) |
Density | 1.4720 |
Shipping Conditions | Ambiens |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Crystallina alba |
Puritas / Analysis Methodus | ≥99.0% (HPLC) |
Lepidium sativum | (1) IR (2) HPLC |
Humor (KF) | ≤0.50% |
Metalla gravis | ≤10ppm |
immunditiam A | ≤0.15% |
impudicitia B | ≤1.0% |
immunditia C | ≤1.0% |
Alia immunitas | ≤0.50% |
Totalis immunditias | ≤1.0% |
Residua solvens | Toluene ≤0.089% |
Test Standard | Enterprise Standard |
Consuetudinem | Intermedia Sorafenib Tosylate (CAS: 475207-59-1) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
Manufacturer cum High puritate et stabulo Quality
Supple Commercial Sorafenib Tosylate (CAS: 475207-59-1) Intermedia:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolamide CAS:
4-Chloro-3-(Trifluoromethyl) phenyl Isocyanate CAS: 327-78-6
Sorafenib Tosylate (CAS: 475207-59-1) est novum genus pharmaci antitumoris multi-scopi, a Germanico Bayer pharmaceutico enucleatum, et in experimentis animali preclinicis antitumorem expansivum ostendit.Sorafenib praesto est in tabulis CC-mg pro administratione oralis adhibenda in curatione RCC et HCC.Sorafenib Tosylate (CAS: 475207-59-1) potest simul afficere cellas tumorem et vasa sanguinis tumorem.Habet duplicem antitumorem effectum: cellam signo transductionis meatus mediante RAF/MEK/ERK obstruere potest ut directe inhibeat tumorem cellularum incrementorum, dum etiam inhibet VEGF et laminae incrementi derivatorum (PDGF) receptores ad impediendum sanguinis tumorem novum formandum. vasis fictilibus, obliquo tumore cellulae incremento inhibito.